Last $73.50 USD
Change Today -0.30 / -0.41%
Volume 180.0
AZNCF On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 9:35 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZNCF) Snapshot

Open
$73.50
Previous Close
$73.80
Day High
$73.50
Day Low
$73.50
52 Week High
05/1/14 - $81.70
52 Week Low
09/10/13 - $48.85
Market Cap
92.8B
Average Volume 10 Days
75.1
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/14
P/E TM
--
Dividend
$3.11
Dividend Yield
4.23%
Current Stock Chart for ASTRAZENECA PLC (AZNCF)

astrazeneca plc (AZNCF) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (AZNCF) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZNCF) Key Developments

Mitsubishi Thnabe Pharma Collaborates with Astrazeneca for Conducting Research on Diabetic Nephropathy

Mitsubishi Thnabe Pharma has collaborated with AstraZeneca. It was reported on August 21, 2014 that the collaboration is aimed at conducting research on diabetic nephropathy. The three-year research is intended to leverage complementary strengths, expertise and assets to certify and progress new research targets and molecules into clinical development. It will be executed in parallel at Mitsubishi Thnabe Pharma's facilities in Japan, and at AstraZeneca's Cardiovascular and Metabolic Disease Innovative Medicines Unit in Moindal, Sweden.

Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology

Illumina, Inc. announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi. Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners' clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.

Pfizer Eyes Actavis And AstraZeneca

Pfizer Inc. (NYSE:PFE) is looking at new targets for acquisitions, Bloomberg reports. Pfizer is making an attempt to acquire AstraZeneca PLC (LSE:AZN). It is also considering other alternatives including Actavis plc (NYSE:ACT). Under U.K. takeover rules Pfizer can make the first steps toward a renewed bid on August 26, 2014. While it weighs that approach, Pfizer also is looking at other possible targets, including Actavis plc (NYSE:ACT), said people familiar with the matter. Pfizer Chief Executive Officer Ian Read has said he’s also looking for a deal that will yield cost reductions and a way to lower Pfizer’s tax rate and access overseas cash. “We will continue to evaluate all opportunities, regardless of size, through the lens of value creation for our shareholders and enhancing the competitiveness of our business,” Joan Campion, a spokeswoman for New York-based Pfizer, said in an e-mail.AstraZeneca declined to comment on Pfizer’s interest, citing the U.K.takeover panel’s rules. David Belian, a spokesman for Actavis, didn’t immediately return a call and e-mail message seeking comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $73.50 USD -0.30

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.64 USD -0.11
Amgen Inc $137.80 USD +0.53
Biogen Idec Inc $342.42 USD -0.57
Bristol-Myers Squibb Co $50.28 USD -0.49
Novo Nordisk A/S kr259.40 DKK +0.60
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 46.1x
Price/Sales 3.6x
Price/Book 4.2x
Price/Cash Flow 46.2x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.